Labetalol for hypertension in pregnancy

Bibliography

• Frick MH, Porsti P. Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension. Br Med J 1976;1(6017):1046-8
   PubMed Web of Science ®Google Scholar
• Sanders GL, Davies DM, Gales GM, et al. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol 1979;8(Suppl 2):149S-51S
   Google Scholar
• Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol 1979;8(Suppl 2):211S-5S
   Google Scholar
• Frishman W, Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol. Am Heart J 1979;98(5):660-5
   PubMed Web of Science ®Google Scholar
• Cocco G, Burkart F, Chu D, Foltath F. Intrinsic sympathomimetic activity of beta-adrenoreceptor blocking agents. Eur J Clin Pharmacol 1978;13:1-4
   PubMed Web of Science ®Google Scholar
• Richards DA, Prichard BN. Clinical pharmacology of labetalol. Br J Clin Pharmacol 1979;8(Suppl 2):89S-93S
   Google Scholar
• Cannon CM, Levy P, Baumann BM, et al. Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ Open 2013;3(3):1-7
   Google Scholar
• Pugsley DJ, Armstrong BK, Nassim MA, Beilin LJ. Controlled comparison of labetalol and propranolol in the management of severe hypertension. Br J Clin Pharmacol 1976;3(4 Suppl 3):777-82
   PubMed Web of Science ®Google Scholar
• Fischer JH, Sarto GE, Hardman J, et al. Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet 2014;53(4):373-83
   PubMed Web of Science ®Google Scholar
• Nylund L, Lunell NO, Lewander R, et al. Labetalol for the treatment of hypertension in pregnancy. Pharmacokinetics and effects on the uteroplacental blood flow. Acta Obstet Gynecol Scand Suppl 1984;118:71-3
   PubMedGoogle Scholar
• Jeong H, Choi S, Song JW, et al. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 2008;38(1):62-75
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012;11:CD002003
   PubMedGoogle Scholar
• Kuyper LM, Khan NA. Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 2014;30(5 Suppl):S47-53
   PubMed Web of Science ®Google Scholar
• Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev 2012;8:CD004643
   Google Scholar
• Magee LA, Pels A, Helewa M, on behalf of the Canadian Hypertensive Disorders of Preganncy (HDP) Working Group. Diagnosis, evaluation and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014;4:105-45
   PubMed Web of Science ®Google Scholar
• Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014;36(5):416-38
   PubMedGoogle Scholar
• Society of Obstetric Medicine of Australia and New Zealand (SOMANZ). 2014. Available from: www.somanz.org/guidelines.asp
   Google Scholar
• Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122(5):1122-31
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. Guidance nice org uk/cg107. 2013
   Google Scholar
• Prichard BN, Richards DA. Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. Br J Clin Pharmacol 1979;8(Suppl 2):239S-44S
   Google Scholar
• Bateman BT, Hernandez-Diaz S, Huybrechts KF, et al. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension 2012;60(4):913-20
   PubMed Web of Science ®Google Scholar
• Gerard J, Blazquez G, Lardoux H, et al. [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. J Gynecol Obstet Biol Reprod (Paris) 1983;12(8):891-900
   PubMedGoogle Scholar
• Gerard J, Blazquez G, Mounac M, et al. [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. Rev Fr Gynecol Obstet 1984;79(11):713-17
   PubMedGoogle Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 9th edition. Lippincott Williams and Wilkins, Philadelphia; 2011
   Google Scholar
• Reprotox. Available from: www.reprotox.org [Accessed 21 September 2014]
   Google Scholar
• Yakoob MY, Bateman BT, Ho E, et al. The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension 2013;62(2):375-81
   PubMed Web of Science ®Google Scholar
• Gillon TER, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international cinical practice guidelines. PLoS One 2014;9(12):e113715
   PubMed Web of Science ®Google Scholar
• Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013;7:CD001449
   PubMed Web of Science ®Google Scholar
• Tavasoli F, Saghafi N, Ghomian N, et al. Comparison of effects of labetalol and hydralazine in treatment of hypertension in patients with severe preeclampsia. Iran J Obstet Gynecol Infertil 2012;15(17):1-7
   Google Scholar
• Nederlandse Vereniging voor Obstetrie Gynaecologie (The Dutch Society of Obstetrics and Gynaecology). Hypertensieve aandoeningen in de zwangerschap. 2011. Available from: www.nvog.nl
   Google Scholar
• Ashe RG, Moodley J, Richards AM, Philpott RH. Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afr Med J 1987;71(6):354-6
   PubMed Web of Science ®Google Scholar
• Baggio MR, Martins WP, Calderon AC, et al. Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. Ultrasound Med Biol 2011;37(1):53-8
   PubMed Web of Science ®Google Scholar
• Harper A, Murnaghan GA. Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. Br J Obstet Gynaecol 1991;98(5):453-9
   PubMedGoogle Scholar
• Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 1987;70(3 Pt 1):328-33
   PubMed Web of Science ®Google Scholar
• Saudan P, Billieux M-H, Pechere A, et al. Which first-line drug to control severe hypertension in pregnancy? A pilot study. Pregnancy Hypertens 2012;2(3):182
   Google Scholar
• Vigil-De GP, Lasso M, Ruiz E, et al. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006;128(1-2):157-62
   PubMed Web of Science ®Google Scholar
• Garden A, Davey DA, Dommisse J. Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. Clin Exp Hypertens B 1982;1(2-3):371-83
   PubMed Web of Science ®Google Scholar
• Aswathkumar R, Gilvaz S. Management of severe hypertension in pregnancy: prospective comparison of labetalol vs nifedipine [abstract]. In: 49th All India Congress of Obstetrics and Gynaecology; 6 – 9 January 2006; Cochin, Kerala, India; 2006. p. 38
   Google Scholar
• Desai BB, Swamy MK, Patil KP. A randomized controlled trial of oral nifedipine vs intravenous labetalol in acute control of blood pressure in hypertensive emergencies of pregnancy. In: 54th All India Congress of Obstetrics and Gynaecology; 5 – 9 January 2011; Cochin, Kerala, India. 2011. p. 179
   Google Scholar
• Elatrous S, Nouira S, Ouanes BL, et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. Intensive Care Med 2002;28(9):1281-6
   PubMed Web of Science ®Google Scholar
• Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG 2012;119(1):78-85
   PubMed Web of Science ®Google Scholar
• Michael CA. Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. Aust N Z J Obstet Gynaecol 1986;26(1):26-9
   PubMed Web of Science ®Google Scholar
• Moore MP, Redman CWG. The treatment of hypertension in pregnancy. Curr Med Res Opin 1982;8:S39-46
   PubMed Web of Science ®Google Scholar
• Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327(7421):955-60
   PubMed Web of Science ®Google Scholar
• Tuffnell DJ, Jankowicz D, Lindow SW, et al. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. BJOG 2005;112(7):875-80
   PubMed Web of Science ®Google Scholar
• Magee L, von Dadelszen P, Rey E, et al. Less-tight ver++sus Tight control of hypertension in pregnancy. New Engl J Med 2015;372(5):407-17
   PubMed Web of Science ®Google Scholar
• Cruickshank DJ, Campbell D, Robertson AA, MacGillivray I. Intra-uterine growth retardation and maternal labetalol treatment in a random allocation controlled study. J Obstet Gynaecol 1992;12:223-7
   Google Scholar
• Li CY, Lao TT, Yu KM, et al. The effect of labetalol on mild pre-eclampsia. Proceedings of 7th Word Congress of Hypertension in Pregnancy; Perugia, Italy; 1990. p. 191
   Google Scholar
• Pickles CJ, Broughton PF, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol 1992;99(12):964-8
   PubMedGoogle Scholar
• Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987;70(3 Pt 1):323-7
   PubMed Web of Science ®Google Scholar
• Walker JJ, Crooks A, Erwin L, Calder AA. Labetalol in pregnancy-induced hypertension: fetal and maternal effects. In: Reilly A, Symonds EM, editors. Amsterdam: 1982. p. 148-60
   Google Scholar
• Lamming GD, Broughton PF, Symonds EM. Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. Clin Exp Hypertens 1980;2(5):865-95
   PubMed Web of Science ®Google Scholar
• Lardoux H, Blazquez G, Leperlier E, Gerard J. [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. Arch Mal Coeur Vaiss 1988;81(Spec No):137-40
   PubMedGoogle Scholar
• Molvi SN, Mir S, Rana VS, et al. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet 2012;285(6):1553-62
   PubMed Web of Science ®Google Scholar
• Plouin PF, Breart G, Maillard F, et al. Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. Br J Obstet Gynaecol 1988;95(9):868-76
   PubMedGoogle Scholar
• Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990;162(4):960-6
   PubMed Web of Science ®Google Scholar
• Subhedar B, Inamdar S, Hariharan C, Subhedar S. Comparison of efficacy of labetalol and methyldopa in patients with pregnancy-induced hypertension. Int J Reprod Contracept Obstet Gynecol 2013;2(1):27-34
   Google Scholar
• Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014;2:CD002252
   PubMed Web of Science ®Google Scholar
• Magee LA, von Dadelszen P, Chan S, et al. The control of hypertension in pregnancy study pilot trial. BJOG 2007;114(6):770.e13-20
   Google Scholar
• von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000;355(9198):87-92
   PubMed Web of Science ®Google Scholar
• von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002;24(12):941-5
   PubMedGoogle Scholar
• El Guindy AA, Nabhan AF. A randomized trial of tight vs. less tight control of mild essential and gestational hypertension in pregnancy. J Perinat Med 2008;36(5):413-18
   PubMed Web of Science ®Google Scholar
• Waterman EJ, Magee LA, Lim KI, et al. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens Pregnancy 2004;23(2):155-69
   PubMed Web of Science ®Google Scholar
• Breastfeeding and the use of human milk. Pediatrics 2012;129(3):e827-41
   PubMed Web of Science ®Google Scholar
• Lunell NO, Kulas J, Rane A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol 1985;28(5):597-9
   PubMed Web of Science ®Google Scholar
• Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988;14(4):217-40
   PubMed Web of Science ®Google Scholar
• The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl 4th Report):555-76
   PubMed Web of Science ®Google Scholar
• Mirpuri J, Patel H, Rhee D, Crowley R. What’s mom on? A case of bradycardia in a premature infant on breast milk. J Invest Med 2008;56:409
   Web of Science ®Google Scholar
• Ehrenstein V, Rothman KJ, Pedersen L, et al. Pregnancy-associated hypertensive disorders and adult cognitive function among Danish conscripts. Am J Epidemiol 2009;170(8):1025-31
   PubMed Web of Science ®Google Scholar
• Seidman DS, Laor A, Gale R, et al. Pre-eclampsia and offspring’s blood pressure, cognitive ability and physical development at 17-years-of-age. Br J Obstet Gynaecol 1991;98(10):1009-14
   PubMedGoogle Scholar
• Whitehouse AJ, Robinson M, Newnham JP, Pennell CE. Do hypertensive diseases of pregnancy disrupt neurocognitive development in offspring? Paediatr Perinat Epidemiol 2012;26(2):101-8
   PubMed Web of Science ®Google Scholar
• Chan WS, Koren G, Barrera M, et al. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010;29(3):271-83
   PubMed Web of Science ®Google Scholar
• Pasker-de Jong PC, Zielhuis GA, van Gelder MM, et al. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG 2010;117(9):1080-6
   PubMed Web of Science ®Google Scholar
• Williams PJ, Morgan L. The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. Pharmgenomics Pers Med 2012;5:37-51
   PubMedGoogle Scholar
• Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009;55(11):1077-8
   PubMed Web of Science ®Google Scholar
• Cooper WO. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors. J Cardiovasc Nurs 2008;23(1):20-4
   PubMed Web of Science ®Google Scholar
• Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int 2012;2012:658310
   PubMedGoogle Scholar
• Walfisch A, Al-maawali A, Moretti ME, et al. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31(6):465-72
   PubMedGoogle Scholar
• Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014;30(5):485-501
   PubMed Web of Science ®Google Scholar
• Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy; a randomised controlled trial. Br J Obstet Gynaecol 2000;107:759-65
   Google Scholar
• Bayliss H, Churchill D, Beevers M, Beevers DG. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for “pharmacological programming” in the first trimester? Hypertens Pregnancy 2002;21(2):161-74
   PubMed Web of Science ®Google Scholar
• Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982;1(8273):647-9
   PubMed Web of Science ®Google Scholar
• Bortolus R, Ricci E, Chatenoud L, Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. Br J Obstet Gynaecol 2000;107(6):792-4
   Google Scholar
• Brown MA, Buddle ML, Farrell T, Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002;187(4):1046-50
   PubMed Web of Science ®Google Scholar
• Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005;193(1):153-63
   PubMed Web of Science ®Google Scholar
• Lactmed. Available from: http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm [Accessed 21 September 2014]
   Google Scholar
• Lalani S, Firoz T, Magee LA, et al. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can 2013;35(3):215-23
   PubMedGoogle Scholar